-
Mashup Score: 7The State of State Biomarker Testing Insurance Coverage Laws - 7 day(s) ago
This Viewpoint discusses laws mandating insurance coverage of biomarker testing to broaden access to care for patients with cancer.
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0PhALLCON Soars to New Heights—Faster, Stronger, but Better? - 7 day(s) ago
In this issue of JAMA, Jabbour and colleagues1 report results from the interim analysis of the PhALLCON randomized trial with ponatinib vs imatinib, combined with reduced-intensity chemotherapy. They found ponatinib to have superior efficacy and a comparable safety profile for frontline treatment of…
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 16
This randomized trial assesses the effect of ponatinib vs imatinib combined with low-intensity chemotherapy on disease remission in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL).
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access - 7 day(s) ago
This clinical care review summarizes government policies for the safe conduct of clinical trials using the telehealth and decentralized clinical trials digital health models.
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 34
This cohort study uses registry data to examine the risk of colorectal cancer (CRC) and CRC-specific death for up to 20 years after having a first colonoscopy with findings negative for CRC.
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 21
This study of 5-year follow-up data from a phase 2 clinical trial examines the association of response with 12 induction instillations of bacillus Calmette-Guèrin (BCG) without maintenance therapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC).
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 54
This review assesses current evidence and emerging treatment strategies for improved survival among patients with metastatic hormone-sensitive prostate cancer and offers recommendations for clinical practice application.
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Association of Skin Microbiome Dynamics With Radiodermatitis in Patients With Breast Cancer - 8 day(s) ago
This observational study assesses the association of skin microbiome baseline composition and dynamics with the severity of radiodermatitis in patients undergoing adjuvant radiotherapy for breast cancer treatment.
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin for Adult Relapsed or Refractory B-Cell ALL - 9 day(s) ago
This phase 1 dose-escalation trial examines whether inotuzumab ozogamicin plus dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) is safe and effective for adults with relapsed or refractory B-cell acute lymphoblastic leukemia or lymphoma (ALL).
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Precision CRC Fecal Immunological Test Screening With f-Hb-Guided Interscreening Intervals - 10 day(s) ago
This cohort study examines the applicability of personalized colorectal cancer (CRC) screening with fecal-hemoglobin (f-Hb)-guided screening intervals to reduce the number of fecal immunological tests and colonoscopy, as well as determine if it demonstrates equivalent efficacy as universal biennial…
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
Viewpoint discusses laws mandating insurance coverage of biomarker testing to broaden access to care for patients with cancer. https://t.co/PJJWPUSFZK https://t.co/TVa6M9EwQd